Biolex

Biolex Therapeutics was a biotechnology firm in the Research Triangle of North Carolina which was founded in 1997 and raised $190 million from investors.

Biolex developed recombinant DNA technology for efficiently producing pharmaceutical proteins in Lemna.

[3] Therapeutic glycosylated proteins, including monoclonal antibodies[4] and interferon (IFN-alpha2b)[5] have been produced using the LEX platform.

[6] Biolex was a privately held company, originally backed by Quaker BioVentures, The Trelys Funds, and Polaris Venture Partners.

In May 2012 Biolex announced that it sold the LEX System to Synthon, a Netherlands-based specialty pharmaceutical company.